QTRX · Quanterix Corporation

Quanterix Corporation announced its Q1 2026 financial results, posting revenue of $36.4 million, a 20% increase from $30.3 million in the prior-year quarter, driven by growth across product, service, and collaboration segments. Product revenue rose to $25.5 million from $20.7 million, service and other revenue to $10.4 million from $8.8 million, while collaboration revenue dipped slightly to $0.6 million. GAAP gross margin contracted to 42.7% from 48.9% due to a new accounting policy shift recording shipping and handling costs in cost of product revenue; adjusted gross margin expanded 120 basis points to 50.9%. Operating expenses climbed to $56.9 million from $41.2 million, primarily from a $19.8 million impairment charge, leading to a GAAP operating loss of $41.4 million versus $26.4 million last year. Adjusted EBITDA loss improved to $9.8 million from $11.3 million, reflecting $85 million in cost synergies from the Akoya acquisition. CEO Everett Cunningham highlighted progress toward cash flow breakeven, with focus on commercial effectiveness, product roadmap, and Alzheimer's diagnostics growth, including milestones like FDA 510(k) decision and clinical studies in H2 2026. The company ended Q1 with $102.6 million in cash and securities, anticipating breakeven in H2 and year-end cash around $100 million with no debt. Guidance remains unchanged at $169-174 million revenue, assuming no academic/pharma market recovery, underscoring disciplined execution amid integration benefits.